Separation & Purification

Teknova and Sartorius look to address critical pain points in AAV bioprocessing

20-Mar-2023 By Jane Byrne

Alpha Teknova Inc is teaming up with Sartorius BIA Separations, part of the Sartorius life sciences group, to help gene therapy companies streamline the downstream purification process.

Donaldson acquires Isolere Bio

21-Feb-2023 By Rachel Arthur

Donaldson Company will acquire Isolere Bio: an early-stage biotech that develops novel and proprietary ‘IsoTag’ reagents and accompanying filtration processes used for the purification and streamlined manufacturing of biopharmaceuticals.

Biotage acquires Astrea Bioseparations

16-Feb-2023 By Rachel Arthur

Biotage will acquire Astrea Bioseparations, a chromatography solutions provider, from Gamma Biosciences: extending its chromatography franchise into the bioprocessing market for biologics and advanced therapeutic customers.

Samsung Biologics on track to open ‘super plant’ in October

28-Jul-2022 By Rachel Arthur

Construction of Samsung Biologics’ Plant 4 is on schedule with operations set to start in October, the company confirmed in its Q2 results this morning.

WuXi Biologics to build CRDMO center in Singapore

21-Jul-2022 By Rachel Arthur

CDMO WuXi Biologics will invest $1.4bn in a 10 year investment plan to expand its research, development, and large-scale drug substance and drug product manufacturing capacity and capabilities in Singapore.

From textiles to therapies: North Carolina’s journey to a booming biotech hub

29-Mar-2022 By Rachel Arthur

While skills shortages present one of the main challenges to the biopharma industry, North Carolina believes its investments in the life science ecosystem have given it a ‘multiple decade jumpstart’ in building a successful biopharma hub for both manufacturing...

Moderna’s Australian mRNA manufacturing facility set to become operational in 2024

24-Mar-2022 By Rachel Arthur

Moderna has finalized a strategic partnership with the Australian government to build an mRNA manufacturing facility in Melbourne: which is expected to produce up to 100 million mRNA respiratory vaccine doses annually.

Flow Eighteen38 to double protein purification capacity

08-Mar-2022 By Rachel Arthur

Flow Eighteen38, a protein sciences division created to facilitate and accelerate antibody characterization and protein purification projects, has announced a €5m ($5.58m) investment into its protein production and biophysical characterization capabilities...

WHO establishes global biomanufacturing training hub in Korea

25-Feb-2022 By Rachel Arthur

A global biomanufacturing training hub will be established in Korea to serve low- and middle-income countries wishing to produce biologicals such as vaccines, insulin, monoclonal antibodies and cancer treatments.

What changes are needed for more connected and continuous manufacturing?

19-Jan-2022 By Jane Byrne

Biopharma manufacturers continue to evaluate opportunities to improve process performance across downstream unit operations.

Donaldson Company strengthens presence in biopharma with Solaris Biotechnology acquisition

23-Nov-2021 By Rachel Arthur

Donaldson Company, Inc., a global provider of filtration products and solutions, has acquired Solaris Biotechnology Srl for around €41m ($46m).

Sartorius launches redesigned filtration unit

17-Nov-2021 By Ben Hargreaves

The vacuum filtration units are suitable for lab-based research in low volumes, with the company stating the update improves speed, capacity, and stability.

NPD Gallery: Technology Insider

04-Oct-2021 By Jane Byrne

We track some of the more recent developments in biopharma manufacturing tech.

Sartorius downplays threat of Chinese regulatory changes to single-use tech

02-Aug-2021 By Nick Taylor

Sartorius has expressed confidence that demand for single-use technologies will be unaffected by changes to the regulation of biologics in China.

Cytiva and Pall to spend $1.5bn on manufacturing capacity expansion, new hires

27-Jul-2021 By Jane Byrne

Cytiva and Pall Corporation, both subsidiaries of Danaher Corporation, have announced they are to invest US$1.5bn to expand manufacturing capacity across 13 sites globally

Pall inks $7m deal with Exothera for suspension based production of viral vectors

19-Jul-2021 By Jane Byrne

Filtration, separation and purification specialist, Pall, has announced a new contract valued at over US$7M with full-service CDMO, Exothera.

NPD Gallery: Technology Insider

19-Jul-2021 By Jane Byrne

We report on some of the latest biopharma industry targeted new releases in terms of technological innovation.

What are some of the dos and don’ts on starter materials for CGT manufacturing?

04-Jun-2021 By Jane Byrne

Raw materials play a vital role in the development of cell and gene (CGT) therapies.

Special Edition: Continuous bioprocessing

Continuous bioprocessing market to be worth nearly $200m within six years

06-May-2021 By Jane Byrne

A new report published by Meticulous Research shows the continuous bioprocessing market is expected to grow at a CAGR of 22.9% from 2020 to 2027 to reach US$197.8m by the end of the period.

NPD Gallery: Technology insider

06-May-2021 By Jane Byrne

What's new in the world of biopharma tech? We track the latest in process innovation equipment releases.

Clean Biologics gains foothold in North American market, adds vaccine and biologics focused CDMO to group

05-May-2021 By Jane Byrne

French pharma services provider, Clean Biologics, has acquired Canadian CDMO, Biodextris, in a move it says will boost its analytical and process development, and early-phase clinical manufacturing and quality control testing services for clients in the...

Sartorius acquires BIA Separations for $423m

05-Oct-2020 By Rachel Arthur

German life science company Sartorius will merge Slovenian purification specialist BIA Separations with Sartorius Stedim Biotech, in a deal worth €360m ($423m).

No one predicted rapid growth of gene therapy market, says CEO

26-Feb-2020 By Ben Hargreaves

After posting revenue growth of 39%, Repligen CEO suggests this was driven by filtration and chromatography franchises, particularly customers in gene therapy.

BIA Separations in deal to expand virus purification offering

20-Feb-2020 By Vassia Barba

In its latest deal, BIA Separations brings to market an elution method developed by the University of Zagreb, which helps preserve viruses’ integrity, infectivity, and potency.

‘High performance’ membrane for in situ cell filtration

10-Dec-2019 By Vassia Barba

Securecell introduces Sephara, an in situ filtration membrane with precise pore size for continuous production of antibodies and exosomes.

Thermo Fisher expands site, boosts biologics processing offering

28-Nov-2019 By Vassia Barba

Thermo Fisher Scientific doubles the capacity of its gene therapy and viral vector processing facility in Alachua, Florida, to provide scalability to customers.

Sartorius in $750m swoop for Danaher Life Science businesses

22-Oct-2019 By Ben Hargreaves

Sartorius is set to acquire three biopharma businesses from Danaher, once the latter company concludes its deal for GE Biopharma.

BIA Separations adds to Cornerstone vector development program

16-Oct-2019 By Vassia Barba

An expansion to BIA Separations' Cornerstone set of processing services for viral vector development adds the use of kryptonase and CIMmultus chromatography device.

July roundup sees flurry of partnership deals

29-Jul-2019 By Ben Hargreaves

The summer months are traditionally slow on movements across the industry, but July saw a number of manufacturing partnership deals take place as companies look ahead to product commercialization.

BIA Separations brings ‘sense of urgency’ to Zolgensma agreement

24-Jul-2019 By Maggie Lynch

AveXis and BIA Separations announce an agreement for the commercial purification process of SMA gene therapy drug Zolgensma and further gene therapy candidates.

Servier taps Pall for biomanufacturing facility operations set-up

23-Jul-2019 By Maggie Lynch

Pall works with Servier to get the latter’s oncology drug production and biomanufacturing up and running to support its Bio-S project.

NIH signs on IDT Biologika to manufacture clinical trial supply

16-Jul-2019 By Maggie Lynch

The NIH has contracted IDT Biologika to manufacture five E. coli master cell banks for BLA, IND, and Phase I/II trial supply.

Sartorius’ $100m Puerto Rico expansion enables greater supply for US industry

26-Jun-2019 By Maggie Lynch

Sartorius’ investment in Puerto Rico site doubles production capacity of manufacturing equipment for the biopharmaceutical industry.

Single-use tech ‘reshaping’ the industry as Thermo Fisher further invests

11-Jun-2019 By Maggie Lynch

Thermo Fisher invests into bioproduction capabilities as ‘single use continues to reshape the face of the industry,’ says single-use technology executive.

WuXi Biologics to build 1.3m-sq-ft manufacturing centre

16-May-2019 By Ben Hargreaves

WuXi Biologics announces its latest expansion, with plans for a drug development and commercial manufacturing site with a potential bioreactor capacity of 144,000L.

Vibalogics makes investment in viral manufacturing to meet increasing demand

09-May-2019 By Maggie Lynch

Vibalogics increases its single-use bioreactor and purification capacity with a new manufacturing line to meet demand for oncolytic virus and viral vector manufacturing services.

Samsung Biologics to provide CDMO support for ‘bio-venture’ firm GI Innovation

09-May-2019 By Melissa Fassbender

Samsung Biologics is providing contract development services for GI Innovation’s pipeline, with the first among five molecules to initiate development immediately, says company representative.

Kite gets freedom to fly after separation from Gilead

08-May-2019 By Vassia Barba

Gilead’s new CEO unties Kite as an independent business unit to give Yescarta’s manufacturer more autonomy in the biotech sky.

Wacker Bio licenses its E. coli based production strain to PhaseBio

06-May-2019 By Maggie Lynch

Wacker licenses E. coli based production strain to PhaseBio for the manufacture of antibody fragment.

Abzena tapped as CMC for Lipum’s biologic development project

20-Mar-2019 By Maggie Lynch

Abzena and Lipum enter agreement for the development of biologics for juvenile idiopathic arthritis, using the former’s proprietary cell line and GMP resources.

‘Can you manufacture consistently?’ The big question in regenerative medicine

11-Mar-2019 By Ben Hargreaves

Regenerative medicine raised $13.3bn in funds during 2018 but investors question whether treatments can be manufactured consistently, according to AMR annual report.

Krystal moves towards ‘full integration’ with gene therapy facility opening

07-Mar-2019 By Ben Hargreaves

Krystal opens cGMP facility for the clinical and commercial manufacture of its lead drug candidate, KB103, and plans to open its second in 2020.

GE continues slim down with $21bn sale of BioPharma business

25-Feb-2019 By Ben Hargreaves

GE announced a change of plans regarding its GE Healthcare business, choosing to sell off the BioPharma business for $21.4bn rather than initiate an IPO.

ATS harnesses electromagnetic technology for cell minimizing unit

21-Feb-2019 By Maggie Lynch

ATS’ SuperTrak Micro minimizes cell sizes through electromagnetic sorting while merging and diverting at full production speed.

Five reasons biologics contract manufacturing will hit $87.6bn by 2027

25-Jan-2019 By Ben Hargreaves

The contract market for bringing biologics through the pipeline to commercialisation is growing at a rapid clip, with a recent report suggesting a high CAGR in the sector.

GE Healthcare and G-CON create platform for advanced therapy production

24-Jan-2019 By Ben Hargreaves

GE Healthcare and G-CON have combined capabilities to offer drug developers ‘readily deployable’ manufacturing platforms for cell therapies and viral vectors.

Boehringer expands commercial biologics production capacity in China

22-Jan-2019 By Ben Hargreaves

Boehringer will increase its capacity for commercial manufacturing of biologics at its Shanghai, China, facility.

DuPont excipient could ‘double to triple’ biologics’ shelf life

14-Jan-2019 By Ben Hargreaves

DuPont has developed an excipient that could be more efficient and stable than current products on the market.

Cambrex continues build-out at former PharmaCore site with $1m investment

11-Dec-2018 By Melissa Fassbender

Cambrex is investing $1m at its High Point, NC-based site, marking the most recent in a series of investments which will see the addition of 1,300 square feet and 15 new employees.